Press Releases and Media
 |
Major International Study Begins on OvPlex™ test |
15 June 2010, Melbourne: Melbourne biotechnology company HealthLinx (ASX:HTX) will today launch a major international trial on the OvPlex™ test, that will see 1150 samples screened using the current five (5) biomarker panels and an additional two (2) biomarkers including the recently described biomarker AGR2.
The multi-site, multi-centre trial that is partially funded with $750,000 from the Victorian Government Victoria's Science Agenda Investment Fund, aims to test whether the two new biomarkers can increase the sensitivity and specificity of OvPlex™ to greater than 97 per cent. The study has been powered to allow direct determination of sensitivity and specificity and will include collaborators form Australia, Singapore and the United Kingdom.
Most Popular
HealthLinx’ OvPlex™ ovarian cancer diagnostic awarded BioSpectrum Asia Product of the Year
5 February 2010, Melbourne: Medical diagnostics company HealthLinx Limited (ASX:HTX) has been awarded the BioSpectrum Asia Product of the Year award 2010 for its ovarian cancer diagnostic OvPlex™. The award was judged by an independent jury of international life sciences experts compiled by BioSpectrum Asia, one of the largest industry magazines in the Asian Pacific region.
The jury judged OvPlex™, along with the Shancol cholera vaccine, as joint winners of the award for 2010. The jury of six included life sciences veteran and leading industry analyst and financier Dr G Steven Burrill of Burrill and Co, Industrial Technology Research Institute vice-president Dr Chungcheng Liu and BioSpectrum Asia chief editor Mr Abraham E Mathew.
OvPlex™ in the news:
New Blood Test Offers Hope For Early Detection Of Ovarian Cancer
9 Aug 2010 - Daily Record (Print)
Lisa Adams, features writer at Scotland's best-selling daily paper the Daily Record, wrote an article about OvPlex™ quoting Dr Cameron Martin, cancer specialist at Spire Murrayfield hospital in Edinburgh:
Dr Martin said: "Ovarian cancer is the most fatal gynaecological cancer. If we can detect it at an earlier stage, patients have a far better outlook."
Check the August 9 issue of the Daily Record for the full article.
Ovarian Cancer - New Commercial Early Stage Test
29 Jun 2010 - ITV News
Filmed at Spire Bushy near Watford by ITN, this ITV News item discusses charity campaigners lobbying MPs for better diagnosis and treatment of this most fatal of cancers. At 1:44 in the short video, Joanne Maunder can be seen preparing to give blood for the OvPlex early stage diagnostic test.
Also on ITN: Ovarian cancer victims call for earlier diagnosis.
HealthLinx gets backing for cancer test
15 Jun 2010 - Sydney Morning Herald
The Victorian government is backing a multi-million dollar trial into a new test for the early detection of ovarian cancer, called OvPlex, which has been developed in Melbourne by biotechnology company HealthLinx.
The Minister for Innovation Gavin Jennings launched a major international second study into the OvPlex ovarian cancer diagnostic test this morning and he said the trials could potentially change the lives of many women in Victoria and around the world. Read more...
HealthLinx identifies novel ovarian cancer biomarker
10 Feb 2010 - CNET News
Australian diagnostics company HealthLinx Limited, along with researchers at the University of Liverpool, have just gotten word from the journal Clinical Science that their manuscript detailing the identification of a novel biomarker in ovarian cancer patients has been accepted for publication. Read more...
New blood test to detect ovarian cancer could save thousands
25 Aug 2009 - Daily Mail
A blood test that could save thousands of women's lives by detecting ovarian cancer at an early stage is to be launched in Britain. Read more...
OvPlex™ official ASX announcements:
5 Jul 2010 - OvPlex now available from new central London location
15 Jun 2010 - Major International Study Begins on OvPlex Test
24 Feb 2010 - OvPlex sales launch in UK on 25 February 2010
17 Feb 2010 - Samples secured for commencement of major OvPlex study
11 Feb 2010 - OvPlex diagnostic clinical trial receives UK ethics approval
10 Feb 2010 - Clinical Science to publish manuscript on HTX005 biomarker
See published article here. (Subscription may be required)
05 Feb 2010 - OvPlex awarded BioSpectrum Asia Product of the year
22 jan 2010 - HealthLinx expands collaboration with Liverpool University
For more information on HealthLinx Ltd, the company that developed OvPlex™, visit the Australian Stock Exchange and enter the search code 'HTX' .
Intus Healthcare
Therapeutic options for proactive people
